Curated News
By: NewsRamp Editorial Staff
May 22, 2026

NeuroOne Restates Q2 Results, Reaffirms FY2026 Revenue Guidance

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • NeuroOne (NMTC) restated Q2 revenue by $0.5M but reaffirms FY2026 guidance of at least $10.5M, signaling stability.
  • A customer order modification at quarter-end caused a $0.5M revenue overstatement; NeuroOne will amend its 10-Q and improve internal controls.
  • Despite the accounting error, NeuroOne's continued growth plans aim to improve surgical outcomes for neurological disorder patients.
  • The error was found during a post-release review just days after the initial filing, prompting a quick restatement.

Impact - Why it Matters

This news matters because it demonstrates NeuroOne's transparency in correcting a financial error while maintaining its revenue forecast, which is crucial for investor confidence in the medtech sector. For patients and healthcare providers, the restatement does not affect the company's ongoing operations or product development, including its innovative electrode and ablation systems that aim to improve surgical outcomes for neurological disorders. It underscores the importance of strong internal controls in high-growth companies.

Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, announced a restatement of its financial results for the quarter ended March 31, 2026. The restatement corrects a revenue overstatement of approximately $0.5 million due to a customer order modification at quarter-end, which also led to a net loss understatement of about $0.3 million. Importantly, the company reaffirmed its product revenue guidance of at least $10.5 million for fiscal year 2026, and stated that no prior periods were impacted. CEO Dave Rosa emphasized that this is a one-time correction and that operations and growth plans remain strong.

The error was identified during a post-release review on May 18, 2026, prompting the Audit Committee to determine that the Form 10-Q should be restated. The company is implementing measures to improve internal controls. NeuroOne markets FDA-cleared products including Evo® Cortical Electrodes, Evo® sEEG Electrodes, and the OneRF® Ablation System, which offer high-definition precision for brain surgeries and minimally invasive procedures. The company is also researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more details, visit nmtc1.com.

This restatement highlights the importance of robust financial controls, especially for a growth-stage medical technology firm. The company’s ability to quickly identify and correct the error, while maintaining its guidance, should reassure investors and partners. The original news release is available on NEWMEDIAWIRE.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Restates Q2 Results, Reaffirms FY2026 Revenue Guidance

blockchain registration record for this content.